FDA Approves Every-8-Week EBGLYSS Dosing for Atopic Dermatitis

The U.S. Food and Drug Administration (FDA) has approved a label expansion for EBGLYSS® (lebrikizumab-lbkz), allowing eligible adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis to transition to an every-eight-week (Q8W) maintenance regimen. The decision provides dosing flexibility for patients who achieve an adequate clinical response after initial treatment, reducing injection frequency to as few as six doses annually.

Targeting IL-13 in Atopic Dermatitis

EBGLYSS, developed by Eli Lilly, is a monoclonal antibody that selectively binds and neutralizes interleukin-13 (IL-13), a central cytokine in the type 2 inflammatory pathway. By blocking IL-13 signaling, the therapy reduces inflammation underlying skin lesions, pruritus, and recurrent flares.

Atopic dermatitis is a chronic inflammatory skin disorder associated with persistent itching, eczema lesions, sleep disruption, and significant quality-of-life burden. Patients with moderate-to-severe disease often require long-term systemic therapy to maintain symptom control and prevent disease recurrence.

Evidence from ADjoin Extension Study

The FDA decision was supported by longitudinal exposure-response modeling and clinical findings from the Phase 3 ADjoin long-term extension study (NCT04392154).

The 32-week study evaluated EBGLYSS 250 mg administered every eight weeks and every four weeks in adults and adolescents who had completed prior pivotal studies, including ADvocate 1 and 2, ADhere, ADore, and ADopt-VA. Data from the extension supported maintenance of clinical response with Q8W dosing in eligible patients, demonstrating durable disease control while reducing treatment frequency. The findings reinforced the long-term efficacy profile of EBGLYSS and supported the newly approved maintenance schedule.

Safety Profile Remains Consistent

Safety outcomes in ADjoin remained consistent with the established profile of EBGLYSS. No new safety signals were identified during the 32-week extension, and no patients discontinued treatment because of adverse events.

The most common adverse reactions reported with EBGLYSS included conjunctivitis, injection-site reactions, and herpes zoster.

Clinical Implications

Peter Lio, M.D., clinical assistant professor of dermatology and pediatrics at Northwestern University and an investigator in the ADjoin study, said the every-eight-week maintenance option provides greater flexibility for patients with moderate-to-severe atopic dermatitis by reducing treatment frequency without requiring mandatory topical therapies.

Kristin Belleson, president and CEO of the National Eczema Association, added that less frequent dosing may help lessen the day-to-day treatment burden while supporting durable disease control.

Commercial Outlook

The approved U.S. regimen begins with a 500 mg loading dose at Weeks 0 and 2, followed by 250 mg every two weeks through Week 16. Patients who achieve adequate response may then transition to maintenance dosing of 250 mg every four weeks or every eight weeks.

Lilly stated the expanded schedule builds on EBGLYSS’ long-term durability and offers eligible patients a maintenance option requiring as few as six injections annually, reducing treatment burden while preserving disease control.

EBGLYSS is approved in the United States, Canada, Japan, and the European Union. Its global Phase 3 program has enrolled more than 1,600 patients across seven major studies, including adolescents, patients with skin of color, and those previously treated with dupilumab. The FDA decision strengthens EBGLYSS’ position in the atopic dermatitis market by providing one of the least frequent biologic maintenance dosing schedules available.

Reference

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis | Eli Lilly and Company